Day: January 16, 2025

Urbo bankas UAB (hereinafter – “the Bank”), company code 112027077, address: Konstitucijos pr.18B, Vilnius. According to 10/01/2025 decision of the Director of the Prudential Supervision Department of the Bank of Lithuania, the Bank was allowed to include the profit for the first nine months of 2024, i.e. EUR 5,000 thousand  Common Equity Tier 1. Pursuant to this permission, on 31 December 2024, the Bank’s capital adequacy ratio increased by 1.86 percentage points to 17.77%. For more information please contact: Julius Ivaška, Head of Business Division, tel. +370 601 04 453, e-mail media@urbo.lt  

Vaisala CorporationInside informationJanuary 16, 2025, at 8:30 a.m. (EET) Inside information: Vaisala’s 2024 operating result (EBIT) higher than estimated earlier and Vaisala provides preliminary information Vaisala Corporation’s 2024 unaudited preliminary operating result (EBIT) was EUR 83 million and net sales were EUR 565 million. On October 24, 2024, Vaisala estimated its full-year 2024 operating result (EBIT) to be in the range of EUR 68–78 million a its net sales to be in the range of EUR 540–570 million. In the fourth quarter 2024, operating result was higher than estimated in both business areas due to higher than estimated net sales and successful cost control. Vaisala’s fourth quarter 2024 and full-year 2024 preliminary net sales by business area were:EUR million Q4/2024 Q4/2023 1-12/2024 1-12/2023Industrial Measurements 65 58 226 227Weather...

Oslo, 16 January 2025 – DNO ASA, the Norwegian oil and gas operator, will publish its Q4 2024 operating and interim financial results on 6 February at 07:00 (CET). A videoconference call with executive management will follow at 14:00 (CET). Today the Company provides an update on production, sales volumes and other selected information for the quarter.Volumes (boepd) Gross operated production Q4 2024 Q3 2024 Q4 2023Kurdistan 74,163 84,212 65,773North Sea 6,602 – –       Net entitlement production Q4 2024 Q3 2024 Q4 2023Kurdistan 17,424 17,607 26,057North Sea 19,031 11,236 16,879       Sales Q4 2024 Q3 2024 Q4 2023Kurdistan 17,424 17,607 26,057North Sea 17,088 15,307 15,628       Equity accounted production (net) Q4 2024 Q3 2024 Q4 2023Côte d’Ivoire         2,988 2,842 3,476Selected...

SIKA EXPANDS ITS GLOBAL FOOTPRINT WITH NEW PLANTS IN SINGAPORE AND CHINA Sika has opened two state-of-the-art plants in Singapore and in Xi’an, Northwest China. The newly built plant in Singapore specializes in the production of mortars, while the Xi’an facility manufactures a full range of Sika products, including tile adhesives, cementitious waterproofing, and flooring solutions. With both plants, Sika will be able to respond better to local market demands, while significantly reducing logistical distances. The highly automated plant in Singapore will cater to local customers in the metropolitan area, home to over six million people. While extensive urban planning has created many green and recreational spaces, Singapore remains the third most densely populated country in the world. This high population density creates a...

PRESS RELEASEJanuary 16, 202520250116_Press Release_Renault Group_2024 Sales Results IN 2024, ALL THE GROUP’S BRANDS ARE GROWING THANKS TO 10 LAUNCHESIn 2024, Renault Group sold 2,264,815 vehicles (+1.3% vs. 2023) worldwideRenault: 1,577,351 vehicles (+1.8% vs. 2023) Dacia: 676,340 vehicles (+2.7% vs. 2023) Alpine: 4,585 vehicles (+5.9% vs. 2023)In Europe1, the Group progressed twice as well as the market, with sales up 3.5%. With 1,599,051 vehicles sold, Renault Group is on the podium of car manufacturers with Sandero as the best-selling car across all channels. Outside Europe, with its International Game Plan, the Renault brand saw its sales increase in Brazil (+10.3%) thanks to Kardian and in South Korea (+80.6%) thanks to the launch of Grand Koleos, the first vehicle of the new Renault Korea entity. The Group...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR 16 JANUARY 2025 RICHEMONT REPORTS STRONG PERFORMANCE WITH SALES UP 10% FOR ITS THIRD QUARTER ENDED 31 DECEMBER 2024 Highlights for the quarter ended 31 December 2024Very solid end to the calendar year with Q3 sales up by 10% at constant and actual exchange ratesHighest ever quarterly sales at € 6.2 billion Double-digit growth in the Americas, Europe, Middle East & Africa and Japan; slower decline in Asia Pacific despite still challenging demand in China Marked improvement over H1 across all business areas, driven by an acceleration at Jewellery Maisons to +14%; Specialist Watchmakers at -8%, ‘Other’ at +11%, including Fashion & Accessories Maisons at +7% Channel performance led by retail, up 11% at constant and actual exchange rates9-month sales at € 16.2 billion, +4% at constant...

Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarterPratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends AGAMREE® (vamorolone) for use in the National Health Service (NHS) in England, Wales and Northern Ireland for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older. This follows confirmation that no appeals were received against the Final Draft Guidance (FDG) recommendation announced on December 10, 2024. Following this, Santhera has already started launch preparations for AGAMREE in the UK and expect first sales in this quarter. AGAMREE is the first and only medicinal product for DMD to have received...

Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fund in relation to AGAMREE® (vamorolone). Idorsia has also recently exercised outstanding warrants held in Santhera on a cashless basis, reinforcing its position as a major shareholder in the Company. Idorsia transfers rights to royalties and milestones for AGAMREE (vamorolone) to R-Bridge Healthcare Fund through a monetization agreement In 2020, Idorsia’s license, collaborative development, and commercialization agreement with ReveraGen BioPharma for AGAMREE was transferred in its entirety to Santhera. As part of this agreement, Idorsia is entitled to development and sales milestones, as well as low single-digit percentage royalties on net...

Harvest volumes Q4 2024 (1)Farming Norway 83.5 thousand tonnes   (FY: 304 thousand tonnes)Farming Scotland 17.0 thousand tonnes   (FY: 66 thousand tonnes)Farming Chile 22.5 thousand tonnes   (FY: 73 thousand tonnes)Farming Canada 5.0 thousand tonnes   (FY: 30 thousand tonnes)Farming Ireland 1.0 thousand tonnes   (FY: 9 thousand tonnes)Farming Faroes 1.0 thousand tonnes   (FY: 9 thousand tonnes)Farming Iceland (Arctic Fish) 3.5 thousand tonnes   (FY: 11 thousand tonnes)Total 133.5 thousand tonnes   (FY: 502 thousand tonnes)       Full year harvest volumes were record-high 502 thousand tonnes in 2024 versus 475 thousand tonnes in 2023, equivalent to a growth of 5.7% In connection with the presentation of the Q3 2024 results, Mowi guided a total harvest volume of 132.1k GWT for Q4 2024. Note:(1) The harvest volumes...

Cayman Islands, January 15, 2025 — Silexion Therapeutics Corp (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,703,703 of the Company’s ordinary shares (or ordinary share equivalents) and warrants to purchase up to 3,703,703 ordinary shares at a combined public offering price of $1.35 per share (or per ordinary share equivalent) and accompanying warrant. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about January 17, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright...